Literature DB >> 22505206

EGCG suppresses prostate cancer cell growth modulating acetylation of androgen receptor by anti-histone acetyltransferase activity.

Yoo-Hyun Lee1, Jieun Kwak, Hyo-Kyoung Choi, Kyung-Chul Choi, Sunoh Kim, Jeongmin Lee, Woojin Jun, Hyun-Jin Park, Ho-Geun Yoon.   

Abstract

Manipulating acetylation status of key gene targets is likely to be crucial for effective cancer therapy. In this study, we utilized green tea catechins, epicatechin (EC), epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) to examine the regulation of androgen receptor acetylation in androgen-dependent prostate cancer cells by histone acetyl-transferase (HAT) activity. EC, EGC and EGCG induced prostate cancer cell death, suppressed agonist-dependent androgen receptor (AR) activation and AR-regulated gene transcription. These results demonstrated a similar tendency to HAT inhibitory activities; EGCG>EGC>EC. The strongest HAT inhibitor among them, EGCG (50 µM), downregulated AR acetylation and finally, AR protein translocation to nucleus from the cytoplasmic compartment was effectively inhibited in the presence of the agonist. These results suggest another mechanism to develop effective therapeutics based on green tea catechins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505206     DOI: 10.3892/ijmm.2012.966

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  32 in total

1.  EGCG prevents PCB-126-induced endothelial cell inflammation via epigenetic modifications of NF-κB target genes in human endothelial cells.

Authors:  Dandan Liu; Jordan T Perkins; Bernhard Hennig
Journal:  J Nutr Biochem       Date:  2015-10-26       Impact factor: 6.048

Review 2.  Nuclear receptors and epigenetic regulation: opportunities for nutritional targeting and disease prevention.

Authors:  Donato F Romagnolo; Janos Zempleni; Ornella I Selmin
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

Review 3.  Influences of the Gut Microbiota on DNA Methylation and Histone Modification.

Authors:  Jianzhong Ye; Wenrui Wu; Yating Li; Lanjuan Li
Journal:  Dig Dis Sci       Date:  2017-03-24       Impact factor: 3.199

4.  A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.

Authors:  Ji Hoon Jung; Miyong Yun; Eun-Jeong Choo; Sun-Hee Kim; Myoung-Seok Jeong; Deok-Beom Jung; Hyemin Lee; Eun-Ok Kim; Nobuo Kato; Bonglee Kim; Sanjay K Srivastava; Kunihiro Kaihatsu; Sung-Hoon Kim
Journal:  Br J Pharmacol       Date:  2015-06-04       Impact factor: 8.739

Review 5.  The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications.

Authors:  Pingping Guo; Wenqi Chen; Huiyu Li; Meiying Li; Lisha Li
Journal:  Pathol Oncol Res       Date:  2018-06-11       Impact factor: 3.201

6.  Calligonum comosum extract inhibits diethylnitrosamine-induced hepatocarcinogenesis in rats.

Authors:  Walied Abdo; Akihiro Hirata; Mostafa Shukry; Tarek Kamal; Essam Abdel-Sattar; Engi Mahrous; Tokuma Yanai
Journal:  Oncol Lett       Date:  2015-06-03       Impact factor: 2.967

7.  Going Green: The Role of the Green Tea Component EGCG in Chemoprevention.

Authors:  Laura Schramm
Journal:  J Carcinog Mutagen       Date:  2013-05-20

Review 8.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

Review 9.  Histone and Non-Histone Targets of Dietary Deacetylase Inhibitors.

Authors:  Eunah Kim; William H Bisson; Christiane V Löhr; David E Williams; Emily Ho; Roderick H Dashwood; Praveen Rajendran
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 10.  Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.

Authors:  Georgios Kallifatidis; James J Hoy; Bal L Lokeshwar
Journal:  Semin Cancer Biol       Date:  2016-06-28       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.